Contents of a Complete Submission for the Evaluation of Proprietary Names
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
April 11, 2016
February 3, 2025
8bbe789c-b7fd-4a76-9e78-6ea3344719df
Related Documents
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product
Guidance DocumentApril 28, 2015Center for Drug Evaluation and Research
Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry
Guidance DocumentSeptember 30, 2016Center for Drug Evaluation and Research
E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER)
Guidance DocumentJuly 18, 2016Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Stay ahead of FDA enforcement
New KeyPedia insights, webinars, and regulatory analysis — straight to your inbox. Unsubscribe anytime.